Adding more content to screening: reactivation of FOXO as a therapeutic strategy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/91485
Title:
Adding more content to screening: reactivation of FOXO as a therapeutic strategy.
Authors:
Zanella, Fabian; Carnero, Amancio
Abstract:
The discovery of novel targets that can be pharmacologically exploited to lead to a better disease outcome has long been an aim of biomedical research. At present, the technology and robotisation available have pushed the search for novel molecules to a high-throughput screening (HTS) context, making it possible to screen several hundreds of compounds or genes in a single day. High-content screenings (HCS) have added a refined complexity to the screening processes, as the information drawn from an image- based assay is more complete than the monoparametric readouts obtained in classical HTS assays. Here, we review the development of HCS platforms to identify molecules influencing FOXO nuclear relocation and activation as pharmacological targets, their applicability and the future directions of the screening field.
Affiliation:
Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain.
Citation:
Adding more content to screening: reactivation of FOXO as a therapeutic strategy. 2009, 11 (10):651-8 Clin Transl Oncol
Journal:
Clinical & Translational Oncology
Issue Date:
Oct-2009
URI:
http://hdl.handle.net/10541/91485
DOI:
10.1007/s12094-009-0420-0
PubMed ID:
19828407
Type:
Article
Language:
en
ISSN:
1699-3055
Appears in Collections:
All Paterson Institute for Cancer Research; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorZanella, Fabianen
dc.contributor.authorCarnero, Amancioen
dc.date.accessioned2010-02-09T14:19:23Z-
dc.date.available2010-02-09T14:19:23Z-
dc.date.issued2009-10-
dc.identifier.citationAdding more content to screening: reactivation of FOXO as a therapeutic strategy. 2009, 11 (10):651-8 Clin Transl Oncolen
dc.identifier.issn1699-3055-
dc.identifier.pmid19828407-
dc.identifier.doi10.1007/s12094-009-0420-0-
dc.identifier.urihttp://hdl.handle.net/10541/91485-
dc.description.abstractThe discovery of novel targets that can be pharmacologically exploited to lead to a better disease outcome has long been an aim of biomedical research. At present, the technology and robotisation available have pushed the search for novel molecules to a high-throughput screening (HTS) context, making it possible to screen several hundreds of compounds or genes in a single day. High-content screenings (HCS) have added a refined complexity to the screening processes, as the information drawn from an image- based assay is more complete than the monoparametric readouts obtained in classical HTS assays. Here, we review the development of HCS platforms to identify molecules influencing FOXO nuclear relocation and activation as pharmacological targets, their applicability and the future directions of the screening field.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshDrug Discovery-
dc.subject.meshForkhead Transcription Factors-
dc.subject.meshHigh-Throughput Screening Assays-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.titleAdding more content to screening: reactivation of FOXO as a therapeutic strategy.en
dc.typeArticleen
dc.contributor.departmentExperimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain.en
dc.identifier.journalClinical & Translational Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.